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Abstract
Background: Ca2+ is known to be involved in a number of metastatic processes including motility
and proliferation which can result in store-depletion of Ca2+. Up regulation of genes which
contribute to store operated channel (SOC) activity may plausibly be necessary for these processes
to take place efficiently. TRPC proteins constitute a family of conserved Ca2+-permeable channels
that have been shown to contribute to SOC activity.
Results: In breast cancer biopsy tissues, TRPC3 and TRPC6 were the predominant TRPC genes
expressed with TRPC3 and TRPC6 being significantly up regulated compared to normal breast
tissue. In the lowly metastatic breast cancer cell line MCF-7, TRPC6 was the chief TRPC gene
expressed while in the highly metastatic breast cancer cell line MDA-MB-231 both TRPC3 and
TRPC6 were the predominant TRPC genes expressed. Western blotting, immunoconfocal analysis
and immunoprecipitation experiments confirmed that the MDA-MB-231 cell line expressed both
TRPC3 and TRPC6 protein with the majority of protein being intracellular. TRPC3 and TRPC6
were found to be in an immunoprecipitatble complex and co-localize within the cell. To
demonstrate the potential of targeting TRP channels in breast cancer, hyperforin reportably a
specific activator of TRPC6 significantly reduced the growth and viability of the breast cancer cell
lines but had no effect on the non-cancerous breast cell line. Silencing of TRPC6 in MDA-MB-231
cells resulted in a significant reduction in cell growth but not viability.
Conclusion: TRPC channels may be potential future targets for breast cancer diagnosis and
therapy and deserve further investigation to evaluate their role in cancer cell physiology.
Introduction
Breast cancer is a leading cause of cancer-associated death
in women [1]. It most commonly metastasizes to the
bone, with 70% of patients who develop bone metastases
dying [2]. Finding early markers of metastasis and devel-
oping effective therapies against their development is a
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priority. Investigation of functional expression of mem-
brane ion channels is an exciting development in cancer
research. Increased expression of voltage-sensitive ion
channels is directly associated with malignancy, as evi-
denced by their role in cell proliferation, migration and
survival [3]. As such, some of these channels have begun
to be developed as targets for cancer drug design [4].
Whilst considerable work has so far been done on K+ and
Na+ channels, surprisingly little is known about the role of
mechanosensitive channels and Ca2+ signalling in cancer.
Both are likely to have a significant role in the cancer proc-
ess and Ca2+ is a regulator of proliferation and apoptosis
[5]. In this regard, a key group of ion channels of increas-
ing prominence are the Transient Receptor Potential
(TRP) family [6]. There is evidence that expression of
TRPV6, TRPM8, TRPM1 and TRPV1 are significantly
altered in human cancer cells [6]. TRPC proteins in
humans (TRPC1, 3, 4, 5, 6 and 7) constitute a family of
conserved Ca2+-permeable cation channels which are acti-
vated in response to agonist-stimulated PIP(2) hydrolysis
and subsequent studies have provided substantial evi-
dence that some TRPCs contribute to SOC activity [7].
TRPC proteins have also been shown to form agonist-
stimulated calcium entry channels that are not store-oper-
ated but are likely regulated by PIP(2) or possibly diacylg-
lycerol [7]. TRPC1 and 6 are also sensors of mechanically
and osmotically induced membrane stretch [8]. In human
PCa LNCaP cells, agonist-mediated stimulation of
alpha1-adrenergic receptors required coupled activation
of TRPC6 channels and nuclear factor of activated T-cells
to promote proliferation [9]. Additionally, in the same
cells, store-operated Ca2+  channels were found to be
important determinants of the transition to androgen-
independent state [10]. Consistent expression of TRPC1,
3, 5, 6 in glioma cell lines and acute patient-derived tis-
sues has been described. These channels gave rise to small,
non-voltage-dependent cation currents that were blocked
by the non-selective TRPC inhibitors GdCl3, 2-APB, or
SKF96365. Importantly, TRPC channels contributed to
the resting conductance of glioma cells and their acute
pharmacological inhibition caused an ~10 mV hyperpo-
larization of the cells' resting potential. Additionally,
chronic application of the TRPC inhibitor SKF96365
caused near complete growth arrest [11]. Finally in liver
tumor samples TRPC6 was expressed more strongly than
in isolated hepatocytes from healthy patients and experi-
ments suggested that TRPC6 may play a role in control of
human hepatoma cell proliferation [12]. Little is known
about canonical TRP (TRPC) ion channels in breast cancer
apart from a few emerging papers to date [13,14], such
channels could play a major role in cellular activities
involved in the cancer process since TRPC channels are
predominantly Ca2+ permeable. The primary aim of this
paper is to determine which TRPC channels are expressed
in breast cancer cell lines and tissues and the roles these
channels may play in cell proliferation.
Experimental details
Materials
A mouse anti-TRPC3 polyclonal antibody was obtained
from the Abnova Corporation and used at a 1:200 dilu-
tion for immunoblotting and 1:20 for immunochemistry.
A rabbit anti-TRPC6 polyclonal antibody was obtained
from Sigma-Aldrich and used at a 1:200 dilution for
immunoblotting and 1:20 for immunochemistry. TBST
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05%
Tween-20). PBS buffer (40 mM Na2HPO4, 10 mM
KH2PO4, and 120 mM NaCl with a resulting pH of 7.2).
Culture of cell lines
Human breast cancer cell lines (MCF-7 and MDA-MB-
231) were cultured in DMEM (Gibco) containing 10%
FBS and 4 mM glutamine with penicillin-streptomycin.
The 'normal' human breast epithelial cell line (MCF-10A)
was cultured in a 1:1 mixture of Dulbecco's modified
Eagle's medium and F12 medium (Gibco, DMEM-F12)
supplemented with 5% FBS, hydrocortisone (0.5 μg/ml),
insulin (10 μg/ml), epidermal growth factor (20 ng/ml),
and penicillin-streptomycin. All cell lines were main-
tained in a 37°C CO2 incubator in 100 mm culture dishes.
RNA extraction from biopsy samples and breast cell lines
An absolutely RNA miniprep kit (Stratagene) was used to
extract total RNA from breast cell lines or homogenized
breast biopsy tissue. cDNA synthesis was conducted using
1  μg of RNA, 1 μg of Oligo (dT)18 and Superscript II
reverse transcriptase (Gibco) according to the manufac-
turers instructions. All samples were tested for absence of
genomic DNA contamination before use.
PCR
Standard PCR reactions were performed with a Hotstar
Taq plus PCR mastermix (Qiagen) under the following
conditions: 95°C for 30 s, 55°C for 15 s, and 72°C for 1
min for 40 cycles. Heating for 5 mins at 95°C preceded
the cycles. The primer concentration used was 0.5 μM. All
primers were tested on known targets before use (refer to
table 1). Nested PCR was used in the analysis of breast
biopsy tissue. A standard PCR was performed using "exter-
nal primers" as described above for 35 cycles. The "exter-
nal primers" were designed approximately 100 bp
upsteam/downstream of the "internal primers" following
this step 1 ul of this PCR reaction was utilized in a new
PCR reaction with "internal primers" in a 100 μl volume
for a further 40 cycles.
Real time PCR
Real time PCR was performed on a DNA Engine Opticon
2 machine with Opticon Monitor™ software. PCR withCancer Cell International 2009, 9:23 http://www.cancerci.com/content/9/1/23
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Table 1: Primers utilized in this investigation
Primer name Primer sequence Expected product size (bp)
TRPC1 F 5'-GTA AGT GGA TTT GCT CTC AT-3' 298 for TRPC1B splice variant
TRPC1 R 5'-TGG TTA ATT TCT TGG ATA AA-3'
TRPC3 F 5'-TAC TCA ACA TGC TAA TTG CTA TGA T-3' 383
TRPC3 R 5'-CAC AGT TGC TTG GCT CTT GTC TTC C-3'
TRPC4 F 5'-CTC TGG TTG TTC TAC TCA ACA TG-3' 781
TRPC4 R 5'-CCT GTT GAC GAG CAA CTT CTT CT-3'
TRPC5 F 5'-GCT CGC AGC CAC CCC AAA GGG AGG A-3' 548
TRPC5 R 5'-CCA ATG TCC CTA CCC TGT TCT CCC AGC TCT C-3'
TRPC6 F 5'-GAA CTT AGC AAT GAA CTG GCA GT-3' 625 or 277
TRPC6 R 5'-CAT ATC ATG CCT ATT ACC CAG GA-3'
TRPC7 F 5'-GTC CGA ATG CAA GGA AAT CT-3' 477
TRPC7 R 5'-TGG GTT GTA TTT GGC ACC TC-3'
TRPM7 F 5'-AAA CCA GTT CTG CCT CCT CCA C-3' 100
TRPM7 R 5'-GTC CAT CGG AAG TCT TAT CTT TCT TTC-3'
TRPM8 F 5'-GAT TTT CAC CAA TGA CCG CCG-3' 502
TRPM8 R 5'-CCCCAGCAGCATTGATGTCG-3'
TRPV6 F 5'-GAG CAG TCC CTG CTG GAA CT-3' 254
TRPV6 R 5'-GGT ACT TCG AGA CAC TGA GG-3'
Cav3.2 F 5'-GAA GGA CAC GCT GCG CGA GT-3' 180
Cav3.2 R 5'-GCA TCC TCC CGT GCC TCC TT-3'
β-actin F 5'-ATG GAT GAT GAT ATC GCC GC-3' 350
β-actin R 5'-ATC TTC TCG CGG TTG GCC TT-3'
TRPC1 F nested 5'-ATGGCGGCCCTGTACCCGAG-3'
TRPC1 R nested 5'-AACACAATGTGCATTCACAG-3'
TRPC3 F nested 5'-AAGTGACTTCCGTTGTGCTC-3'
TRPC3 R nested 5'-AGGTTGCTGCATCATTCACA-3'
TRPC4 F nested 5'-TGTGACCAATGTCAAAGCAC-3'
TRPC4 R nested 5'-CTAACACACATTGTTCACTG-3'
TRPC5 F nested 5'-CACATCACAACCACGACG-3'
TRPC5 R nested 5'-ACTTGCCTGTAACAGATCGG-3'
TRPC6 F nested 5'-CAA CCA GAA ACA GAA GCA TG-3'
TRPC6 R nested 5'-CTC GCA ATG AAT GAT GCT GC-3'
TRPC7 F nested 5'-CACAGTTCTCCTGGACAGAA-3'
TRPC7 R nested 5'-TTACTTCAGATAAGCCGAAT-3'Cancer Cell International 2009, 9:23 http://www.cancerci.com/content/9/1/23
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SYBR® Green PCR Master Mix (Qiagen) was performed
under the following conditions: 95°C for 30 s, 55°C for
15 s, and 72°C for 1 min for 40 cycles. Heating for 5 min
at 95°C preceded the cycles. Melting curves and agarose
gel electrophoresis were performed to verify the specificity
of the products. As variations in cDNA quality within dif-
ferent samples could occur, β-actin was included as an
internal control. By subtracting the β-actin threshold (Ct)
value from the TRPC Ct value of each sample, the cDNA
quality of each sample is taken into account. The relative
quantification (R) of the mRNA levels in each individual
sample was calculated according to following equation: R
= EΔCt (control-sample) [15]. The real time PCR efficiency of
each TRPC amplicon (E) was calculated according to the
method described previously [16].
Protein methods
Cellular protein extracts at a concentration of 1 mg/mL
were mixed with SDS sample buffer (Sigma-Aldrich) and
5 μg of protein were loaded per lane and separated on acr-
ylamide 4% – 20% gradient Tris-glycine minigels (Cam-
brex). The proteins were transferred to nitrocellulose
membrane for 3 h at 4°C; transfer was verified using Pon-
ceau red (Sigma) and the blots were blocked with a solu-
tion containing 2.5% skimmed milk and 2.5% bovine
serum albumin (BSA) in TBST overnight at 4°C before
probing with specific antibodies. The antibodies were
diluted in TBST with 0.5% skimmed milk and 0.5% BSA
and incubated with the blot for 4 h at room temperature.
Following four 10-min washes with TBST (with constant
agitation) at room temperature, the blots were incubated
with anti-mouse or anti-rabbit horseradish peroxidase-
conjugated secondary antibodies (DAKO- at the manufac-
turers' suggested concentrations) as appropriate, and
diluted in TBST with 0.5% skimmed milk and 0.5% BSA
for 2 h at room temperature. The blots were again washed
as before and then developed with an enhanced chemilu-
minescence Western blot kit (Amersham). Immunopre-
cipitations were carried out with a Classic Seize kit from
Pierce. As controls, the immunoprecipitation was per-
formed in the absence of immunoprecipitating antibody
or with a isotype control antibody.
Immunocytochemistry
Sterile 13 mm diameter glass coverslips were placed in 24
well costar plates. To each well 1 ml of cell suspension
were seeded at a density of 2 × 104 cells/ml and then
allowed to grow for 48 h. The cells were washed twice with
PBS and then incubated with concanavalin-A (FITC con-
jugated) for 10 mins at room temperature in PBS with 1%
BSA. Cells were washed twice in PBS for 1 min and then
fixed in 2% paraformaldehyde for 7 mins at room temper-
ature. The cells were washed four times with PBS and sub-
sequently incubated in saponin (0.1%) in PBS for 5 mins
at room temperature. The permeabilization solution was
aspirated, and the cells were washed four times in PBS
before being blocked with 8% BSA in PBS for 30 mins.
Cells were again washed twice with PBS for 5 min and
excess liquid was removed before addition of TRPC anti-
bodies (1/20 dilution) in 1% BSA in PBS for 1 h. A further
four PBS washes were performed before the cells were
incubated with either an alexifluor 568 conjugated anti-
rabbit IgG (1:100) or a FITC conjugated anti-mouse IgG
(1:100) in PBS with 1% BSA for 30 mins at room temper-
ature in the dark. Four 5 min PBS washes were performed
in the dark and coverslips were mounted in Vectashield
(Vector Laboratories Inc.) and allowed to set overnight at
4°C. Controls to assess auto-fluorescence or non-specific
labeling were also performed and consisted of treatment
with 1% BSA without either primary antibody, secondary
antibody or both. Confocal microscopy was performed on
a Leica 650T instrument using 568 and 488 nm filters and
analysis performed with Leica confocal software using a
cross section tool. Images were analyzed with excitation at
both 568 and 488 nm and each singly to rule out 'cross'
bleed from either wavelength.
Silencing of TRPC6
Transfection was accomplished using a double transfec-
tion procedure using the following target sequences for
TRPC6 (SiRNA1: AACGAGAGCCAGGACTATCTG;
SiRNA2: AAGACGGCTGCCCGCAAGCCC; SiRNACon:
AM4635-Ambion) Briefly, 24-well plates were seeded at
2.5 × 104 cells/well 24 h prior to transfection. Transfection
mixes were set-up with 0.2 μg of siRNA in 50 μl of Opti-
mem and 1 μl of lipofectamine in 50 μl of Optimem (per
well). Transfection mixes were applied to the cells for 6
hours, subsequently removed and replaced with 1 ml of
growth media. After 48 hours the cells were removed with
trypsin and reseeded into 24-well plates and the transfec-
tion repeated as above. Seventy two hours after this sec-
ond transfection the levels of TRPC6 protein was
ascertained by SDS-PAGE electrophoresis and western
blotting as described in the section above.
Viability Assay
Cell viability was assayed using a trypan blue exclusion
assay. Cells were removed with trypsin-EDTA and mixed
with 0.4% trypan blue in PBS for 5 mins at room temper-
ature. Subsequently the number of cells which were able
to exclude the dye was counted.
MTT assay
To six well dishes 600 μl of fresh medium and 150 μl of 5
mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] were added to the wells and
incubated at 37°C for 2 h. The solution was removed and
replaced by 890 μl of DMSO and 110 μl of Glycine buffer
(0.1 M glycine, 0.1 M NaCl, pH 10.5) for 10 mins. TheCancer Cell International 2009, 9:23 http://www.cancerci.com/content/9/1/23
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numbers of viable cells were then quantified by measur-
ing the absorbance at 570 nm with a spectrophotometer.
Data analysis
Data were analyzed by one-way ANOVA. Differences were
taken as statistically significant when P < 0.05.
Results
Expression of TRPC mRNA in normal and breast cancer 
biopsy tissue
Our aims were to determine which TRP channel sub-types
are expressed in normal and cancer breast biopsy tissues.
mRNA was prepared from seven breast tissue samples
obtained by biopsy of which three were found to be nor-
mal and four were diagnosed as cancerous. The mRNA
was converted to cDNA and TRPC sub-type specific prim-
ers (table 1) were utilized in a nested PCR design to con-
firm the expression of TRPC mRNA. Note that a nested
Expression of TRPC mRNA in breast cancer biopsy tissue Figure 1
Expression of TRPC mRNA in breast cancer biopsy tissue. (A) PCR amplification with TRPC subtype specific primers 
of cDNA prepared from breast biopsy tissue (normal [-], tumour [+] and negative control [c]). The PCR reactions were sepa-
rated on an agarose gel. Molecular weight markers in base pairs are shown to the right of the gels. As a control for the integrity 
of each cDNA sample β-actin was also analysed. (B) Relative expression of TRPC subtype specific mRNA in cDNA prepared 
from normal and tumour breast biopsy tissue. All data normalized to TRPC6 expression in sample 4.
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PCR design was chosen since a single PCR amplification
program (of 40 cycles) gave inconsistent results when
attempted from breast tissues. Following PCR amplifica-
tion all samples were separated on agarose gels and
stained for DNA (Fig 1A). TRPC1 and TRPC3 were
expressed in all samples; TRPC4, TRPC5 and TRPC7
expression was not observed in any of the samples; TRPC6
was expressed only in the cancer tissues. Note TRPC2 is a
pseudogene in humans and was not tested. All primers
were tested on known targets before use. Subsequently
real-time PCR was utilized to compare the relative
amounts of TRPC sub-types in the breast tissue biopsy
samples (Fig 1B). Our results confirm that TRPC6 is not
present in the normal breast tissue, while it is present in
the cancer tissues (n = 5 for each sample). TRPC3 is
present in normal tissues but it is significantly up regu-
lated in the cancer tissues by an average of over five fold
(F = 5.4 p = 2.5 n = 5). No significant up regulation of
TRPC1 was found in the breast cancer tissues compared to
the normal tissues (F = 5.3 p = 0.069 n = 5).
Expression of TRPC mRNA in breast cancer epithelial cell lines Figure 2
Expression of TRPC mRNA in breast cancer epithelial cell lines. (A) PCR with TRPC subtype specific primers was uti-
lized to examine the expression of TRPC mRNAs in cDNA prepared from MCF-10A, MCF-7 and MDA-MB-231 cell lines. The 
PCR reactions were separated on an agarose gel. Molecular weight markers in base pairs are shown to the right of the gel. As 
a control for the integrity of each cDNA sample β-actin was also analysed. (B) Relative expression of TRPC subtype specific 
mRNAs in cDNA prepared from MCF-10A, MCF-7 and MDA-MB-231 cells. All data normalized to TRPC3 expression in MCF-
7 cells.
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Expression of TRPC mRNA in breast cancer epithelial cell 
lines
Breast cell lines derived from cancer tissues are useful
tools to understand the molecular factors involved in can-
cer and metastasis. In this study we chose three breast cell
lines to investigate TRPC expression: MCF-10A (a non
cancerous/transformed cell line), MCF-7 (lowly-meta-
static cancer cell line) and MDA-MB-231 (highly-meta-
static cancer cell line). mRNA was prepared from these cell
lines and converted to cDNA. PCR amplification using
TRPC sub-type specific primers was utilized and the PCR
products were separated on agarose gels and visualized
with a DNA stain (Fig 2A). PCR primers were designed to
identify the existence of previously reported splice vari-
ants. For TRPC3 the main PCR products observed were
larger in size (500 to 550 bp) to that expected (383 bp),
this was found upon sequencing to correspond to a
TRPC3β splice variant as reported previously [17]. For
TRPC6 the PCR product found in the MDA-MB-231 cells
was similar in size to that found in the cancer tissues from
Fig 1. In the MCF-7 cells two splice-variants were visual-
ized the full length expected PCR product (625 bp) and a
predominant shorter splice variant (277 bp) these were
subsequently sequenced and found to correspond to the
splice variants (TRPC6 and TRPC6γ) as reported previ-
ously [14]. Real-time PCR was again utilized to compare
the relative expression of TRPC sub-types in these three
cell lines (Fig 2B). The results also shown in table 2 indi-
cated that TRPC4 and TRPC7 are not expressed in any of
the cell lines; a small amount of TRPC1 was found in all
three cell lines; in MCF-7 cells a small amount of TRPC5
was present while the predominant TRPC subtype
expressed was TRPC6. In MDA-MB-231 cells TRPC3 and
TRPC6 were the predominant TRPC sub-types expressed.
The difference between TRPC3 and TRPC6 expression in
MDA-MB-231 cells was not significant at the 95% level (F
= 0.22, p = 0.65 n = 5). Differences between TRPC6
expression in MCF-7 and MDA-MB-231 was significantly
different at 95% level (F = 48.5, p = 4.4 n = 5) but this
could be accounted for by consideration of the fact that
MCF-7 cells are on average larger than MDA-MB-231 cells
and therefore possess a larger plasma membrane [18].
Protein expression and interaction of TRPC6 and TRPC3 
in breast cancer epithelial cell lines
Extracts of protein were made from MCF-10A, MCF-7 and
MDA-MB-231 breast cell lines and separated by SDS-
PAGE. Following blotting to nitrocellulose the blots were
probed with antibodies to TRPC6 (Fig 3A) and TRPC3
(Fig 3B). MCF-7 and MDA-MB-231 but not MCF-10A cells
expressed TRPC6. As a positive control HEK cells trans-
fected with a TRPC6 expression clone were also blotted.
The results suggest that the MDA-MB-231 cells contained
TRPC6 protein, which was close, or near the size of the
full-length published clone, while the MCF-7 cells con-
tained TRPC6 protein of a predominantly shorter form
(possibly due to splicing observed in Fig 2). TRPC3 pro-
tein was observed only in the MDA-MB-231 cells and the
size of this protein was close to the size observed from
expression of the published sequence of TRPC3 in trans-
fected HEK cells. Since the MDA-MB-231 cells had a sim-
ilar amount of TRPC3 and TRPC6 mRNA expression we
speculated that they might form a complex in these cells
as they are reported to do so in other cells [19]. To confirm
this we performed immunoprecipitation assays on pro-
tein extracted from MDA-MB-231 cells (Fig 3B) using anti-
bodies to TRPC3 and TRPC6. Following SDS-PAGE and
western blotting of the immunocomplexes the blots were
probed with antibodies to TRPC3 or TRPC6. The results
revealed that TRPC3 can immunoprecipitate TRPC6 and
visa versa. No TRPC3/TRPC6 complexes were observed in
the absence of an immunoprecipitating antibody or with
isotype control antibodies.
Localization and co-localization of TRPC6 and TRPC3 in 
breast cancer epithelial cell lines
Our PCR and protein results suggested that TRPC6 and/or
TRPC3 were the predominant TRPC sub-types expressed
Table 2: Relative expressions of TRPC channel sub-types in non-cancerous and cancerous breast cell lines
MCF-10A MCF-7 MDA-MB-231
TRPC1 2.3 × 10-6 +/- 1.6 × 10-6 1.5 × 10-7 +/- 3.9 × 10-8 5.0 × 10-4 +/- 5.0 × 10-4
TRPC3 0 0 0.36 +/- 0.19
TRPC4 00
TRPC5 0 0.0012 +/- 7.3 × 10-4
TRPC6 0 1 (normalized) 0.46 +/- 0.08
TRPC7 000Cancer Cell International 2009, 9:23 http://www.cancerci.com/content/9/1/23
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as mRNA in the MCF-7 and MDA-MB-231 cell lines. To
identify the localization of these TRPC channels in these
cell lines we utilized immunochemistry staining with
TRPC6 and TRPC3 specific antibodies. The MCF-7 and
MDA-MB-231 cells were fixed and subsequently stained
with a concanavalin-FITC conjugate. Following permeabi-
lization the cells were probed with antibodies specific to
TRPC6 or TRPC3 and visualized by confocal microscopy
(Fig 4A, n = 4). TRPC6 was expressed in MCF-7 and MDA-
MB-231 cells but only a small fraction of protein (10 and
3% respectively) was expressed on the plasma membrane.
TRPC3 was expressed in MDA-MB-231 cells (Fig 4B, not
tested in MCF-7 or MCF-10A cells) and the localization
was predominantly intracellular with 4% of protein being
expressed on the plasma membrane. MCF-10A cells did
not express TRPC6 (Fig 4C). Co-staining of MDA-MB-231
cells with TRPC3 and TRPC6 antibodies revealed a similar
co-localization (Fig 4D).
Effect of a TRPC6 activator and gene silencing of TRPC6 
on growth of breast epithelial cell lines
Hyperforin was reported as a specific activator of TRPC6
compared to other TRPC channels [20]. Since TRPC6 was
up regulated in MCF-7 and MDA-MB-231 cells compared
to MCF-10A cells we decided to investigate the effect of
this lipophillic compound on cell growth. The results (Fig
Expression and immunoprecipitation of TRPC6 and TRPC3 protein in breast cancer epithelial cell lines Figure 3
Expression and immunoprecipitation of TRPC6 and TRPC3 protein in breast cancer epithelial cell lines. (A) 
SDS-PAGE separation and Western blot analysis of protein extracts prepared from MCF-10A, MCF-7 and MDA-MB-231 cell 
lines. The blot was probed with a TRPC6 (top panel) or TRPC3 (lower panel) specific antibodies. As a TRPC6 or TRPC3 con-
trol protein extracts prepared from HEK cells transfected with a TRPC6 or TRPC3 expression plasmid and mock-transfected 
HEK cells were also separated. As a loading control the blots were also probed with an antibody to β-actin. (B) Immunoprecip-
tation of TRPC6 and TRPC3 in MDA-MB-231 cells. Total protein extracts prepared from MDA-MB-231 cells were immuno-
precipitated with specific antibodies to TRPC3 or TRPC6 or isotype antibody/no antibody as control. The total protein 
extracts and immunoprecipitations were separated on SDS-PAGE gels and Western blotted with antibodies to TRPC3 or 
TRPC6 (indicated below each blot). Sizes of marker proteins (kDa) are indicated to the right of all blots.
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5A) indicated that for the MCF-10A cell line no significant
change in the growth occurred when hyperforin was
applied for 24, 48 or 72 hrs at a concentration of 10 μm
or 1 μm (F = 0.23 p = 0.68 n = 5 for 72 hrs). In contrast
(Fig 5A) for the MCF-7 and MDA-MB-231 cells a signifi-
cant reduction in cell growth was noted (for 72 hrs F = 31
p = 0.010 n = 5; F = 33 p = 0.006 n = 5 respectively). No
significant effect was seen with hyperforin at concentra-
tions of 0.1 μm or lower for all three cell lines (data not
shown). The effect of hyperforin on viability was also
ascertained at 72 hrs post addition at concentrations of 10
μm and 1 μm (Fig 5B). No significant effect was observed
in the MCF-10A cell line at 1 μM (F = 0.11 p = 0.68 n = 5),
but a significant effect was seen for MCF-7 and MDA-MB-
231 cell lines at 1 μm (F = 39 p = 0.001 n = 5; F = 56 p =
0.0005 n = 5). A double SiRNA transfection protocol was
used to ensure complete knockdown of TRPC6 in MDA-
MB-231 cell lines (Fig 5C). Two independent SiRNA's
were transfected and their effects on cell growth was ascer-
tained using an MTT assay (Fig 5D). The results indicate a
significant effect on cell growth at 72 hrs post transfection
Localization and co-localization of TRPC6 and TRPC3 in breast cancer epithelial cell lines Figure 4
Localization and co-localization of TRPC6 and TRPC3 in breast cancer epithelial cell lines. (A) Immunofloures-
cent confocal images of TRPC6 protein expression in MCF-7 and MDA-MB-231 cell lines. Cells were treated with a concanav-
alin-FITC conjugate to stain the plasma membrane before permeabilization and probing with a TRPC6 specific antibody. Scale 
bar represents 20 μM. (B) Immunoflourescent confocal images of TRPC3 protein expression in MDA-MB-231 cells. Cells were 
treated with a concanavalin-FITC conjugate to stain the plasma membrane before permeabilization and probing with a TRPC3 
specific antibody. The TRPC3/6 and conacavalin-FITC images were merged to indicate co-localization of the plasma membrane 
with TRPC3/6 expression. Scale bar represents 20 μM. (C) Immunoflourescent confocal images to determine TRPC6 protein 
expression in MCF-10A cells. Cells were treated with a concanavalin-FITC conjugate to stain the plasma membrane before 
permeabilization and probing with a TRPC6 specific antibody. Scale bar represents 40 μM. (D) Co-localization of TRPC6 and 
TRPC3 in MDA-MB-231 cells. Images were merged to indicate co-localization of TRPC3 and TRPC6 antibody staining. Scale 
bar represents 32 μM.
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compared to cells transfected with a control SiRNA con-
trol (F = 102 p = 0.002 n = 5; F = 87 p=0.004 n = 5).
Discussion
The ability of Ca2+ signalling to regulate pathways such as
proliferation and apoptosis suggests that therapies that
modulate Ca2+ signalling in cancer cells might be a thera-
peutic option [5]. Modulating the activity of Ca2+ chan-
nels and pumps that are aberrantly expressed in cancer
cells might sufficiently disrupt Ca2+ homeostasis to selec-
tively target cancer cells [5]. The primary question to ask is
which Ca2+channels are expressed in cancer cells? To date
there is incomplete information as to the expression of
TRP channels in normal and cancer breast tissues. Our
major conclusions from this research are listed below:
Effect of TRPC6 activators and gene silencing of TRPC6 on growth of breast cancer epithelial cell lines Figure 5
Effect of TRPC6 activators and gene silencing of TRPC6 on growth of breast cancer epithelial cell lines. (A) 
MCF-10A, MCF-7 and MDA-MB-231 cell lines were seeded into six-well plates and incubated for 24 hours at 37°C. Subse-
quently, hyperforin was added at a concentration of 10 and 1 μM and the cells were incubated at 37°C. As controls, cells were 
also mock-treated with DMSO (which was used to dissolve the hyperforin). At 0, 24, 48 and 72 hours post incubation cell 
growth was measured using a MTT assay (black square 10 μM, grey square 1 μM hyperforin and empty square mock-treated). 
(B) MCF-10A, MCF-7 and MDA-MB-231 cell lines were seeded into six-well plates and incubated for 24 hours at 37°C. Subse-
quently, hyperforin was added at a concentration of 10 and 1 μM and the cells were incubated at 37°C. As controls, cells were 
also mock-treated with DMSO (which was used to dissolve the hyperforin). At 72 hours post incubation viability was measured 
and normalized against the mock-infected cells (black square 10 μM and grey square 1 μM hyperforin). (C) TRPC6 in MDA-
MB-231 cells was silenced using a SiRNA double transfection method. At 72 hours post the second transfection the levels of 
TRPC6 was ascertained by protein extraction and Western blotting. As loading controls the lower part of the gel was 
removed and probed with an antibody to β-actin. Two SiRNAs were utilized and compared to a SiRNA control. (D) TRPC6 in 
MDA-MB-231 cells was silenced using siRNA transfection. At 72 hours post the second transfection cell growth was ascer-
tained using a MTT assay. Two SiRNAs were utilized and compared to a SiRNA control.
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1. Our experiments suggested that normal breast tis-
sues expressed the TRPC1 and TRPC3 genes. Compar-
ison of normal and breast cancer biopsy tissues
indicated a significant alteration in TRPC channel
expression both in terms of channel type expressed
and levels of channel expression. In breast cancer
biopsy tissues TRPC6 was expressed and appeared to
be the predominant TRPC channel expressed. Addi-
tionally TRPC3 appeared to be significantly up regu-
lated in breast cancer tissues. Of course our
experiments could not distinguish which cell types
these TRPC channels were expressed in, since the
breast tissue could contain a variety of cell types.
2. In the epithelial non-cancerous cell line MCF-10A
only relatively very low amounts of TRPC1 expression
was observed. In lowly metastatic breast cancer cell
line MCF-7 the predominant channel expressed was a
short splice variant of TRPC6. In the highly metastatic
breast cancer cell line MDA-MB-231 the predominant
TRPC channels expressed were TRPC3 and TRPC6 (of
longer splice form variants). The amounts of TRPC3
and TRPC6 expressed in the MDA-MB-231 cell line
were comparable in level, which leads us to speculate
that they may form heteromultimers. The sizes of PCR
products for TRPC3 and C6 found in the cancer tissues
appeared to be consistent to that found in the MDA-
MB-231 cell line.
3. Protein expression of TRPC3 and TRPC6 in breast
cancer cell lines appeared to be consistent with the
PCR results. TRPC6 and TRPC3 expression was
observed in the MDA-MB-231 cell line with the major-
ity of protein being expressed in an intracellular loca-
tion.
4. Our data provides strong evidence that TRPC3 and
TRPC6 form heteromutimeric channels in breast can-
cer epithelial cell line MDA-MB-231, which is consist-
ent with previous reports of TRPC3/6 expression [19].
5. Hyperforin a specific activator of TRPC6 produced a
significant reduction in cell growth for the breast can-
cer cell lines, while the non-cancerous breast cell line
was unaffected. Viability was significantly reduced in
the breast cancer cell lines. TRPC6 activation is known
to promote cell proliferation. This is an opposite result
which is obtained here when using hyperforin how-
ever it may be expected that overactivation of TRPC6
by hyperforin could cause a disruption in Ca2+ signal-
ling hence affecting cell proliferation. In an earlier
study, hyperforin induced apoptosis and inhibited the
growth of various human and rat tumour cell lines in
vivo, [21]. Our results provide preliminary functional
data that a rationale to target TRPC channels in breast
cancer cells may have some promise.
6. Complete silencing of TRPC6 in MDA-MB-231 cells
using transfected SiRNA resulted in a significant reduc-
tion in cell growth but not viability.
On the whole our results with the MCF-7 cell line confer
with the recent report by Bolanz et al [22] who found that
TRPC6 and TRPV6 are the predominant TRP channels
expressed in the lowly metastatic cell line T47D. Interest-
ingly our data suggests that in the highly metastatic cell
line MDA-MB-231 TRPV6 was down regulated and TRPC3
was up regulated. Our results are also consistent with the
previous report by El Hiani et al [13] who suggested that,
in MCF-7 cells, TRPC1 and TRPC6 are the most likely can-
didates for the highly selective Ca2+ current described in
these cells. We propose that TRPC6 is the major TRPC
channel expressed in MCF-7 cells. However correlation of
the permeation and pharmacological profiles of the cati-
onic current in MCF-7 cells as described by El Hiani et al,
[13] with those described for TRPC6 shows a number of
notable differences. The authors of that paper suggest that
the cationic channels in MCF-7 cells are probably hetero-
multimers that include both TRPC6 and TRPC1 together
with some other TRP members. Given the presence of
TRPV6 and TRPC6 in MCF-7 cells we support this view.
More recently Guilbert et al [14] demonstrated that
TRPC6 was expressed and functional in breast cancer epi-
thelial cells and that this channel was overexpressed in
tumour tissues without any correlation with tumour
grade, ER expression and lymph node metastasis. TRPC
proteins constitute a family of conserved Ca2+-permeable
cation channels which are activated in response to ago-
nist-stimulated PIP(2) hydrolysis and subsequent studies
have provided substantial evidence that some TRPCs con-
tribute to SOC activity [7]. Since Ca2+ is known to be
involved in a number of metastatic processes including
motility and proliferation [5] these processes may result
in store-depletion thus up regulation of genes which con-
tribute to SOC activity may plausibly be necessary for
these processes to take place efficiently.
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